25 results about "Cerebral ischaemia" patented technology

This invention discloses a class of aminosalicylic acid derivative compounds, their pharmaceutical compositions, and uses. The aminosalicylic acid derivatives of this invention can significantly improve ischemic symptoms in rats with a cerebral ischemia-reperfusion model, and these compounds have broad application prospects in the preparation of drugs for the prevention and treatment of stroke.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a PSD-95 PDZ2 peptidomimetic inhibitor and application thereof. A series of compounds are designed and synthesized by taking a tetrapeptide ETAV as a template, a structure-activity relationship of the compounds with PSD-95 PDZ2 is systematically studied, and an optimal compound 32-2, i.e., the PSD-95 PDZ2 peptidomimetic inhibitor, is screened, a structural formula of which is shown as formula (I), the PSD-95 PDZ2 peptidomimetic inhibitor has very excellent plasma stability, and exhibits significant neuroprotective activity in in-vivo and in-vitro biological activity evaluation, significantly reduces cerebral infarction caused by cerebral ischemia-reperfusion injury, and can be used for preparing a drug for treating ischemic stroke. (I).

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

This invention relates to the fields of pharmaceuticals and nanomedicine, specifically disclosing the preparation of a dual-targeting liposome drug delivery system and its application in stroke. The dual-targeting liposome drug delivery system comprises neutrophils, artemisinin, edaravone, and liposomes. The liposomes co-load artemisinin and edaravone, and their surfaces are modified with sialic acid derivatives and phosphatidylserine to form liposome nanomedicines. The neutrophils act as carriers, transporting the drug across the brain border (BBB) ​​and targeting it to the ischemic brain region. This dual-targeting strategy achieves precise two-stage drug delivery to the ischemic brain region. This delivery system can inhibit NLRP3 inflammasome activation, reduce pyroptosis, and promote microglial polarization towards the M2 anti-inflammatory phenotype, thereby effectively treating cerebral ischemia-reperfusion injury or ischemic stroke.

The present application relates to the technical field of nano-preparation, in particular to an extracellular vesicle-liposome hybrid nanoparticle and a preparation method and application thereof. The extracellular vesicle-liposome hybrid nanoparticle provided by the present application significantly improves the ability of drugs to cross the blood-brain barrier and the target enrichment efficiency of ischemic lesions in the brain through active targeting modification; the specific response release of drugs is realized by using the high active oxygen microenvironment of the lesion, non-specific distribution of drugs is reduced, and the systemic toxic side effects are reduced; ultimately, a multi-target point synergistic treatment system capable of synchronously regulating neural cell apoptosis, glial cell inflammatory activation, brain microvascular endothelial cell ferroptosis and the structural integrity of the blood-brain barrier is constructed, the problem that the effect of traditional single target point intervention is limited is broken through from the root, and a more efficient, safe and precise new treatment strategy is provided for cerebral ischemia-reperfusion injury.

The application belongs to the technical field of biological medicine, and particularly relates to umbilical cord mesenchymal stem cells and a preparation method and application thereof. The preparation method takes umbilical cord Wharton's jelly as raw material, and obtains high-purity umbilical cord mesenchymal stem cells through cleaning treatment, tissue block preparation, serum-free culture and liquid change subculture. The culture conditions and operation parameters are strictly controlled in the preparation process, the MSC serum-free culture medium and trypsin substitutes are used, so that the cell activity and purity can be guaranteed. The umbilical cord mesenchymal stem cells have no obvious toxicity and tumorigenic risk under a safe dose, and have no damage to organs in long-term use. The umbilical cord mesenchymal stem cells can significantly improve the motor dysfunction after cerebral ischemia, reduce the volume of cerebral ischemic injury, protect the integrity of the blood-brain barrier, reduce the neuroinflammatory response, and play a multi-dimensional role in brain tissue protection and repair, thereby providing a new effective means for the treatment of ischemic stroke, and having important clinical transformation value and application prospect.

This invention provides a traditional Chinese medicine compound preparation and its application in the preparation of drugs for treating cardiovascular and cerebrovascular diseases, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine compound preparation comprises the following raw materials in parts by weight: 10-20 parts bee pollen, 8-15 parts curcumin, 5-10 parts γ-aminobutyric acid, 5-12 parts Litsea cubeba leaf, 10-20 parts hawthorn, 5-10 parts Lindera strychnifolia leaf, 10-20 parts kudzu root, 5-12 parts ginseng, 8-15 parts Polygonatum sibiricum, 6-12 parts Sophora japonica flower bud, 3-8 parts tangerine peel, and 1-5 parts L-cysteine. This invention significantly improves the water solubility, stability, and bioavailability of curcumin by constructing a chlorophyll zinc / LDH nanosheet composite carrier to load curcumin. A compound preparation of traditional Chinese medicine was prepared by combining a complex loaded with curcumin with various food and medicine homologous ingredients. This traditional Chinese medicine compound preparation can significantly reduce whole blood viscosity, plasma viscosity and platelet aggregation rate in rats with acute blood stasis model, has anti-thrombotic effect, and significantly promotes the recovery of neurological function in rats with focal cerebral ischemia and reduces the volume of cerebral infarction.

This invention, entitled "A Pharmaceutical Composition, Formulation, Preparation Method, and Application for Alleviating Cerebral Ischemia-Reperfusion Injury," belongs to the field of pharmaceutical technology. The technical problem to be solved is to improve the efficacy of drugs in preventing and / or treating cerebral ischemia-reperfusion injury. The key technical solution is a pharmaceutical composition for alleviating cerebral ischemia-reperfusion injury, comprising sinapic acid and a second therapeutic agent, wherein the second therapeutic agent comprises at least one of edaravone, citicoline, and tetramethylpyrazine.

Described are methods and systems for transcervical access of the cerebral arterial vasculature and treatment of cerebral occlusions, including ischemic stroke. The methods and devices may include methods and devices which may provide aspiration and passive flow reversal, those which protect the cerebral penumbra during the procedure to minimize injury to brain, as well as distal catheters and devices to remove an occlusion. The methods and devices that provide passive flow reversal may also offer to the user a degree of flow control. Devices and methods which provide a way to securely close the access site in the carotid artery to avoid the potentially devastating consequences of a transcervical hematoma are also described.

This invention belongs to the field of tea beverage production technology, specifically a method for producing Osmanthus Green Brick Tea beverage, including raw material pretreatment, extraction, cooling and auxiliary material addition, filtration and homogenization, sterilization and bottling. In the extraction step, green brick tea powder and sweet tea are weighed according to the formula, purified water is added, and the extraction temperature is set to 80℃. Osmanthus flowers are added at the 8th minute of extraction, and the temperature is maintained for 10 minutes. In the cooling and auxiliary material addition step, the tea soup is transferred to a cooling device, cooled to room temperature, and then sodium bicarbonate and vitamin C are added and stirred until completely dissolved. In the sterilization and bottling step, sterilization is performed at 121℃ under high pressure for 2 minutes, and the product is then filled into sealed containers under aseptic conditions to obtain the finished product. By combining sweet tea and green brick tea, this method not only aids digestion and regulates fat metabolism, but also effectively prevents various diseases caused by free radicals, such as tumors, cerebral ischemia, and arteriosclerosis, providing health and wellness benefits.

The application discloses application of bupropion hydrochloride tablets (75mg) in preparation of a medicine for treating stroke, and belongs to the technical field of new purposes of medicines. The core verifies the efficacy and safety of the medicine of the specification through systematic animal tests, aims at the problems of post-stroke neural function defect, motor dysfunction and insufficient neural plasticity, adopts a line plug method to prepare a rat focal cerebral ischemia (MCAO) model, sets multiple control tests, and explores the dosing effect of an equivalent dose of the bupropion hydrochloride tablets (75mg). The test results show that the medicine can significantly reduce the neural function defect score of the model animals, improve the motor coordination ability and the limb usage rate, increase the content of brain-derived neurotrophic factor (BDNF) in the brain, promote the repair of neural plasticity, and is safer than a high-dose scheme and has no obvious adverse reactions. Through complete animal test data, the application proves the effectiveness and safety of the bupropion hydrochloride tablets (75mg) in treating stroke, provides solid test basis for clinical conversion and application of the bupropion hydrochloride tablets (75mg), and has important medical application value.

The present disclosure provides methods of suppressing the activation of microglial cells, methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of ameliorating or treating specific diseases that affect the CNS by nasally administering an anti-CD3 antibody.

The application provides a time-sequential drug controlled-release multifunctional intracranial stent and a preparation method, relates to the technical field of vascular stents, and comprises a stent base made of a Fe-based metal material; and, from inside to outside on the surface of the stent base, a bottom coating layer composed of iron oxide nanotubes, wherein the surface of the iron oxide nanotubes is modified by polydopamine and loaded with rapamycin; a middle coating layer formed by the complex of beta-rich silk fibroin and sodium heparin; and a surface coating layer formed by the complex of silk fibroin and edaravone; wherein the setting positions of the surface coating layer, the middle coating layer and the bottom coating layer correspond to the time sequence of drug release in each coating layer, so that the corresponding drugs are released at different stages after the stent base is placed in a blood vessel, so as to adapt to the pathological evolution process in the blood vessel repair process. The application solves the problems of cerebral ischemia-reperfusion injury and vascular restenosis after the current vascular stent is placed in a cerebral blood vessel.

This invention discloses an adaptive drug delivery system for ischemic stroke, its preparation method, and its application. MMP-2 responsive peptide-drug dimers are loaded onto the surface of mesoporous polydopamine for intervention or treatment of cerebral ischemia-reperfusion injury. The system allows for targeted drug delivery based on individual differences in disease progression among patients, precisely promoting brain injury repair. This invention applies MMP-2 responsive peptides to the treatment of ischemic stroke, using mesoporous polydopamine as a drug carrier, providing reactive sites and loading space for efficient drug loading. The chemical reaction between catechol on the polydopamine surface and the thiol groups on the MMP-2 responsive peptides loads the peptide-drug dimers, thereby achieving responsive drug release on the carrier surface. Simultaneously, this invention utilizes the ability of polydopamine to scavenge reactive oxygen species (ROS), rapidly clearing local ROS and reducing acute damage caused by ischemic stroke.

This invention discloses an injury-related endogenous polypeptide and its applications. The invention employs a "single-model initial screening – multi-model cross-validation" strategy, using an acute lung injury (ALI) model as the screening set and partial hepatectomy (PHx) and cerebral ischemia-reperfusion injury (tMCAO) models as the validation set. Combined with liquid chromatography-tandem mass spectrometry (LC-MS / MS) technology, a group of serum endogenous polypeptides was screened. These polypeptides are novel epitope fragments generated by specific enzymatic digestion of precursor proteins such as fibrinogen α-chain and hemoglobin α / β subunits in the tissue injury microenvironment. Their expression levels are extremely low in healthy serum but exhibit explosive upregulation in injured states. Experiments have confirmed that this group of polypeptides shows significant responses in acute lung injury, liver injury, and cerebral ischemia-reperfusion injury models, and can serve as broad-spectrum biomarkers for multi-tissue injury, providing a novel detection target for the early diagnosis of multi-tissue injury in acute and critical clinical settings.

The application belongs to the technical field of traditional Chinese medicine, and discloses application of uniform lily rehmannia polysaccharide in preparation of a medicine for treating cerebral ischemia, wherein the uniform lily rehmannia polysaccharide is composed of galactose, glucose and fructose in a molar ratio of 2.25:18.98:78.77. The uniform lily rehmannia polysaccharide obtained by the application has fixed components, and the uniform lily rehmannia polysaccharide protects brain tissues from damage caused by cerebral ischemia by regulating cGAS-STING signal transmission, which greatly promotes the industrialization process of lily rehmannia and the application range thereof.

Disclosed in the present invention are salicylic acid derivative compounds and the use thereof. The compounds can significantly relieve ischemic symptoms of cerebral ischemia-reperfusion model rats. The compounds have broad application prospects in the preparation of drugs for preventing and treating cerebral stroke.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The application discloses application of 2,3-dihydroxyacetophenone in treating ischemic diseases, the compound has pharmacological effects of resisting brain damage of mice caused by cerebral ischemia, and has pharmacological activities of resisting neuron damage caused by oxygen-glucose deprivation, and is expected to be developed into a drug for treating ischemic diseases.

The application discloses application of sh-SLK in preparation of a preparation for relieving cerebral ischemia-reperfusion injury, and relates to the technical field of gene targeting drugs. An effective active component of the preparation comprises short hairpin RNA sh-SLK capable of targeting and specifically silencing STE20-like kinase gene expression. The preparation is loaded in a recombinant virus carrier, and is formulated into a lateral cerebral ventricle injection dosage form; the preparation is delivered to brain tissues through a brain stereotactic technique, so that high-efficiency expression of sh-SLK is established in ischemic brain tissues, and then the activity of SLK is specifically inhibited.